Genzyme raises $141 million for general division
This article was originally published in Clinica
US healthcare company Genzyme raised $141 million net from the recent offering of nearly 2.9 million shares in its general division priced at $51.25 each. This followed a smaller offering a few weeks earlier of shares in Genzyme's other division, Genzyme Tissue Repair (see Clinica No 676, p 12).
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.